DFTX

Definium Therapeutics has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$32.97 level is supported by the book value on its balance sheet.

Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following…

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder.

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD.

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets.

Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.

Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12.

Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clinically meaningful, placebo adjusted improvements in anxiety measures.

Definium Therapeutics' LSD eased the symptoms of anxiety, the company said Monday as shares took off again.